Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.
It is also developing R21/Matrix-M adjuvant malaria vaccine.
Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | 0.99 Increased by +70.69% | 1.64 Decreased by -39.63% |
| May 10, 24 | -1.05 Increased by +69.21% | -1.06 Increased by +0.94% |
| Feb 28, 24 | -1.44 Increased by +36.84% | -0.45 Decreased by -220.00% |
| Nov 9, 23 | -1.26 Increased by +41.40% | -1.83 Increased by +31.15% |
| Aug 8, 23 | 0.58 Increased by +108.88% | -1.39 Increased by +141.73% |
| May 9, 23 | -3.41 Decreased by -233.20% | -3.46 Increased by +1.45% |
| Feb 28, 23 | -2.28 Increased by +79.61% | -0.92 Decreased by -147.83% |
| Nov 8, 22 | -2.15 Increased by +50.12% | 1.57 Decreased by -236.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 84.51 M Increased by +283.03% | -121.30 M Increased by +7.25% | Decreased by -143.53% Increased by +75.78% |
| Jun 30, 24 | 415.48 M Decreased by -2.11% | 162.38 M Increased by +179.93% | Increased by +39.08% Increased by +185.95% |
| Mar 31, 24 | 93.86 M Increased by +15.94% | -147.55 M Increased by +49.80% | Decreased by -157.21% Increased by +56.70% |
| Dec 31, 23 | 291.34 M Increased by +1.22% | -178.39 M Increased by +2.12% | Decreased by -61.23% Increased by +3.30% |
| Sep 30, 23 | 22.06 M Decreased by -97.00% | -130.78 M Increased by +22.44% | Decreased by -592.71% Decreased by -2.48 K% |
| Jun 30, 23 | 424.43 M Increased by +128.28% | 58.01 M Increased by +111.36% | Increased by +13.67% Increased by +104.98% |
| Mar 31, 23 | 80.95 M Decreased by -88.50% | -293.90 M Decreased by -244.49% | Decreased by -363.07% Decreased by -1.36 K% |
| Dec 31, 22 | 287.83 M Increased by +29.53% | -182.25 M Increased by +78.46% | Decreased by -63.32% Increased by +83.37% |